Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation
- 1 March 2006
- journal article
- clinical trial
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 113 (3) , 163-166
- https://doi.org/10.1111/j.1600-0404.2005.00566.x
Abstract
Therapy of acute exacerbations of multiple sclerosis (MS) with high-dose intravenous methylprednisolone (IVMP) has shortened the recovery period after relapses, but the mechanisms responsible for the beneficial effects of IVMP in attacks have not been clearly established. Our purpose was to analyze the effect of IVMP on the expression of chemokine receptor 5 (CCR5) protein in blood in acute MS exacerbation.Blood samples were collected from 10 patients with an acute MS exacerbation and the levels of CCR5 on CD4(+) and CD8(+) T cells and CD14(+) monocytes were analyzed by using flow cytometry before IVMP, 24 h, 1 and 3 weeks after commencement of treatment.During the 3-week period the percentages of CCR5-expressing CD4(+) T cells and CD8(+) T cells tended to decrease (P = 0.09 and 0.05, respectively), but the effect did not reach statistical significance. No marked changes were found in the percentage of CCR5-expressing CD14(+) cells.A tendency to a reduction of CCR5-expressing CD4(+) and CD8(+) blood cells induced by IVMP suggests inhibition of their potential to transmigrate into the central nervous system, which is consistent with the short-term beneficial effect of IVMP in acute exacerbation of MS.Keywords
This publication has 19 references indexed in Scilit:
- Expression of Th1/Th2-Related Chemokine Receptors on Peripheral T Cells and Correlation with Clinical Disease Activity in Patients with Multiple SclerosisEuropean Neurology, 2004
- Corticosteroids treatmentJournal of the Neurological Sciences, 2004
- Chemokines: multiple levels of leukocyte migration control☆Trends in Immunology, 2004
- Endothelial cells of the blood-brain barrier: a target for glucocorticoids and estrogens?Frontiers in Bioscience-Landmark, 2004
- Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effectsClinical and Experimental Immunology, 2002
- A correlative triad of gadolinium‐DTPA MRI, EDSS, and CSF‐MBP in relapsing multiple sclerosis patients treated with high‐dose intravenous methylprednisoloneNeurology, 1992
- A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.Journal of Neurology, Neurosurgery & Psychiatry, 1987
- High‐dose intravenous methylprednisolone in the treatment of multiple sclerosisNeurology, 1986
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983